ACTIVATION is a new resource designed to provide up-to-date information on Dendreon's step-by-step journey…Read More
Posted by: , Seattle, Washington
Welcome to ACTIVATION, a new feature on Dendreon.com. As a company centered on putting patients first, we’ve created this site to give you an inside look at what’s happening behind the scenes as we prepare for what we hope will be the approval of the first active cellular immunotherapy (ACI) product, sipuleucel-T, for men with advanced prostate cancer. …Read More
Posted by: , Vice President of Facilities and Engineering
The Dendreon team has been working tirelessly over recent months on the build out of our New Jersey facility in order to expand capacity and provide sipuleucel-T to patients as quickly as possible. …Read More
Posted by: , Chief Information Officer
One of the most exciting aspects of sipuleucel-T is that – if approved by the FDA – it will be the first in a new class of cancer treatments and unlike any other therapy available for advanced prostate cancer patients. What makes sipuleucel-T so unique is …Read More
Posted by: , Senior Director, Supply Operations
In 2010, it is estimated that over three-quarters of a million men will have prostate cancer [Mattson Jack Group, 2009 Cancer Metric Database] and will be seeking treatment. The green dots on the visual below depict where these patients live. …Read More
Posted by: , President and Chief Executive Officer
One of Dendreon’s crowning achievements was the positive results of the Phase 3 IMPACT study in April 2009. This pivotal study was the largest of its kind conducted in men with metastatic castrate-resistant prostate cancer, and we were very encouraged by the outcome. Our next accomplishment was compiling these data into our Biologics License Application (BLA) …Read More
Posted by: , Senior Director of Government Affairs
Yesterday, Dendreon broke ground in Atlanta. I attended the ribbon-cutting ceremony at the newest Dendreon manufacturing facility in Union City, Georgia, part of Atlanta’s new Opportunity Zone. The 160,000 square-foot facility is located at the Majestic Airport Center in South Fulton County, and September 30th marked the first “official” day of construction. …Read More
Posted by: , Senior Vice President, Operations
Dendreon’s work extends far beyond our home base in Seattle, Washington. While our Seattle-based team has been working hard on the pending BLA amendment, things have also been ramping up at our commercial manufacturing facility in Morris Plains, New Jersey. …Read More
Posted by: , Ph.D., Chief Scientific Officer
For more than a decade, I’ve had the exciting opportunity to work on the clinical development of sipuleucel-T, which may be the first FDA approved active cellular immunotherapy (ACI) product. ACI is a novel approach to cancer treatment that harnesses the power of a patient’s own immune system to attack cancer cells. …Read More
